Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis

Completed · Phase 3

Conditions studied: Tinea Pedis, Tinea Cruris, Tinea Corporis

In brief

The purpose of this study is to examine the long-term safety of treating recurrent episodes of tinea pedis for 14 days for each recurrence and recurrent episodes of tinea corporis or tinea cruris for 7 days for each recurrence with Product 33525.

Key facts

Study ID
NCT01349998
Run by
Tinea Pharmaceuticals
People needed
604
Starts
2011-05-01
Expected to finish
2012-09-01
Last updated by the study team
2013-01-23

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.